Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Immune Disorders Infectious Diseases Companies

Sanaria procures US grant for malaria research

This article was originally published in Scrip

Executive Summary

Sanaria, a private company based in Rockville, Maryland, and the University of Maryland Biotechnology Institute have been awarded a $600,000 phase 1 small business innovation research (SBIR) grant from the US National Institute of Allergy and Infectious Diseases to support R&D efforts to genetically engineer mosquitoes that can enhance Sanaria's whole-parasite malaria vaccine production process. Sanaria plans to begin the first human trials of its malaria vaccine in 2009. It claims that its goal is to develop and commercialise a malaria sporozoite vaccine against Plasmodium falciparum.

Table

View full table

Topics

Tags:
Immune Disorders Infectious Diseases Companies
Latest Headlines

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth

AbbVie Claims Rinvoq Superiority To Dupixent In AD

Merck Investors Keeping A Close Watch On Winrevair Uptake

See All
UsernamePublicRestriction

Register

SC030955

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By